|
Volumn 346, Issue 22, 2002, Pages 1692-1698
|
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
a a a a a a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
CD4 ANTIGEN;
CD8 ANTIGEN;
GLYCOSYLATED HEMOGLOBIN;
HOKT3 GAMMA 1 (ALANYLALANINE);
MONOCLONAL ANTIBODY CD3;
OKT 3;
UNCLASSIFIED DRUG;
ADOLESCENT;
ADULT;
ANEMIA;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG EFFECT;
DRUG MECHANISM;
FEMALE;
FEVER;
HUMAN;
INSULIN DEPENDENT DIABETES MELLITUS;
INSULIN RESPONSE;
INSULIN SYNTHESIS;
MALE;
METABOLIC REGULATION;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
RASH;
SCHOOL CHILD;
T LYMPHOCYTE;
ADOLESCENT;
ADULT;
ANTIBODIES, MONOCLONAL;
ANTIGENS, CD3;
C-PEPTIDE;
CD4-CD8 RATIO;
CHILD;
CYTOKINES;
DIABETES MELLITUS, TYPE 1;
FEMALE;
HEMOGLOBIN A, GLYCOSYLATED;
HUMANS;
LYMPHOCYTE COUNT;
MALE;
|
EID: 0037198420
PISSN: 00284793
EISSN: None
Source Type: Journal
DOI: 10.1056/NEJMoa012864 Document Type: Article |
Times cited : (1073)
|
References (38)
|